Jazz Pharmaceuticals
Clinical trials sponsored by Jazz Pharmaceuticals, explained in plain language.
A biopharmaceutical company focused on neuroscience and oncology treatments.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a slow start with CBD oil tame Hard-to-Control seizures?
Disease control Not yet recruitingThis trial tests whether a gradual dosing schedule of cannabidiol oral solution (CBD-OS) can help reduce seizures in adults with Lennox-Gastaut syndrome, a severe form of epilepsy. Participants will take CBD oil alongside their usual seizure medications. The study measures how ma…
Phase: PHASE4 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can CBD tame seizures in severe childhood epilepsy? a major trial aims to find out
Disease control Not yet recruitingThis phase 3 trial is testing whether a cannabidiol oral solution (CBD-OS) can safely reduce seizures in people aged 1 year and older with developmental and epileptic encephalopathy (DEE), a group of severe epilepsy syndromes. Participants receive either CBD or a placebo twice da…
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a new drug cut seizure days in juvenile myoclonic epilepsy?
Disease control Not yet recruitingThis trial tests whether an experimental drug called JZP926 can safely reduce the number of days people aged 10 and older experience myoclonic seizures—brief, shock-like jerks—due to juvenile myoclonic epilepsy. Participants are randomly assigned to receive either JZP926 or a pla…
Phase: PHASE2, PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New dosing options for xywav could help fight daytime sleepiness
Symptom relief Not yet recruitingThis Phase 3 study tests whether expanded dosing regimens of Xywav can safely reduce excessive daytime sleepiness in adults with narcolepsy or idiopathic hypersomnia. About 108 participants will receive either Xywav or a placebo in a randomized withdrawal design. The main goal is…
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC